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Highlights 
 Cells are covered by a dense, protective glycan layer, the glycocalyx 
 Viruses, bacteria and fungi exploit these glycans to gain entry to the host 
 The mucus layer covering host cell epithelia sheds invaders 
 Milk oligosaccharides can serve as protective decoys 
 This review describes the structural mechanisms of this molecular arms race 
  
Abstract 
The critical first step of a microbial infection is usually the attachment of pathogens to host 
cell glycans. Targets on host tissues are in particular the histo-blood group antigens, which 
are present in rich diversity in the mucus layer and on the underlying mucosa. Recent 
structural and functional studies have revealed significant new insight into the molecular 
mechanisms, explaining why individuals with certain blood groups are at increased risk of 
some infections. The most prominent example of blood-group-associated diseases is 
cholera, caused by infection with Vibrio cholerae. Many other microbial pathogens, e.g. 
Pseudomonas aeruginosa infecting the airways, and enterotoxigenic Escherichia coli (ETEC) 
causing traveler’s diarrhea, also bind to histo-blood group antigens, but show a less clear 
correlation with blood group phenotype. Yet other pathogens, e.g. norovirus and 
Helicobacter pylori, recognize HBGAs differently depending on the strain. In all cases, milk 
oligosaccharides can aid the hosts’ defenses, acting as natural receptor decoys, and anti-
infectious therapy can be designed along similar strategies. In this review, we focus on 
important infections of humans, but the molecular mechanisms are of general relevance to a 
broad range of microbial infections of humans and animals. 
 
Introduction 
The battle between pathogens and their hosts is a constant race of evolution and 
adaptation. Once inside the host, either through the airways or the gastrointestinal tract, the 
pathogens must fight their way to the underlying cells. The mucus layer provides the first 
protective barrier of the underlying tissues (reviewed by [1]), and is essentially kept sterile 
by the constant secretion of mucus from goblet cells and the shedding of its top layer. This is 
true in particular for the colon, which has a second, inner mucus layer that is impermeable 
to bacteria. The mucus consists of a network of heavily glycosylated proteins, containing 
negatively charged carbohydrates and a significant amount of neutral, fucosylated sugars. 
The underlying mucous membrane, the mucosa, contains glycoconjugates including both 
lipids and proteins, resulting in a dense layer of glycans called the glycocalyx. This layer 
serves as a protective layer, helping to keep the pathogens at bay. However, many 
pathogens have evolved an ability to take advantage of these glycans, and use them as 
receptors for host cell adhesion or entry [2,3]. 
Especially well-characterized carbohydrate-based antigens are the histo-blood group 
antigens (HBGAs), which include the ABH and Lewis antigens. The ABH blood group system is 
named after the expression of antigens by red blood cells. HBGAs are also present on 
epithelial and endothelial cells throughout the body, and as soluble oligosaccharides in most 
body fluids except cerebrospinal fluid. Many pathogens use these antigens to adhere to host 
cells, and the interplay between pathogens and HBGAs is believed to promote the antigen 
diversity we see today [4,5*]. Individuals have different active glycosyltransferases, leading 
to a large variety of oligosaccharides, whose expression varies greatly between tissues and 
even between tissue parts. A rich display of HBGAs is found in particular in the 
gastrointestinal tract and in the mucus layer covering it. This variation provides an advantage 
against pathogens, which rapidly evolve to maintain their competitive edge.  
HBGAs are synthesized from precursor antigens and modified by the actions of different 
glycosyltransferases (Figure 1; reviewed by [4]). The simplest ABH antigens are the H 
antigens characteristic of blood group O, which can be converted into A or B antigens by 
the action of the A or B glycosyltransferases, respectively. ABH and precursor antigens 
can be fucosylated on GlcNAc, creating the Lewis antigens. The fucosyltransferase 
Secretor/FUT2 can add the so-called Secretor fucose. This enzyme is lacking in 20% of 
the European and North American population, resulting in the so-called non-secretor 
phenotype characterized by the absence of all ABH antigens from mucus and secretions like 
saliva and human milk. Nevertheless, non-secretors can still express the simplest 
fucosylated Lewis antigens. In addition, symbiotic host microbes are known to contribute to 
intestinal fucosylation [6*]. 
The severity and susceptibility of many infectious diseases correlate with blood group 
phenotype [7]. So far, the understanding of the molecular mechanisms underlying this 
phenomenon has been very limited. This has changed recently with the determination of 
several high-resolution crystal structures of relevant protein-HBGA complexes. The gained 
insights are the topic of this review.  
Infections of the gastrointestinal tract 
Infection by enteric pathogens generally occurs through the fecal-oral route, caused by poor 
hygiene, consumption of contaminated food or water, or by exposure to infectious aerosols 
that are produced by vomiting. Some pathogens, such as Helicobacter pylori, are in addition 
transmitted through the oral-oral route, and others, e.g. Vibrio cholerae, can also survive in 
aquatic reservoirs, without any contact with feces. 
Viral infections 
Noroviruses (NoVs) and rotaviruses (RVs) are the two most important causes of acute 
gastroenteritis in humans. Both of them are ‘non-enveloped’ viruses, which means that they 
are encased by a protein capsid lacking a lipid envelope. Viruses replicate and evolve very 
rapidly, giving rise to a large number of different strains with different receptor profiles that 
enable them to conquer different niches (reviewed by [8*,9*,10,11*]). Among their known 
cellular receptors are sialylated structures and HBGAs. Secretors are particularly susceptible 
to NoV and RV infections [12]. These individuals express HBGAs in their body fluids, mucus 
and gastrointestinal epithelial cells, therefore it is plausible that they are at higher risk of 
infection. While many children in the world are routinely vaccinated against RV infections, 
there is currently no vaccine against NoV infection.  
The first examples of human pathogens, for which the molecular basis of blood group 
dependence was elucidated, are NoVs [13,14*]. They are single-stranded RNA viruses 
belonging to the Caliciviridae. Both major NoV genogroups, GI and GII, are known to infect 
humans and bind HBGAs in the high micromolar range [15]. GI includes the well-known 
Norwalk virus, causing winter-vomiting disease. This genogroup mainly targets individuals 
with blood group O, while people with blood group B have a lower risk of infection [16]. In 
contrast, GII NoVs do not discriminate between different blood groups [17,18]. The first X-
ray structure of a NoV was published in 1999 (PDB ID 1IHM [19]*). Its viral capsid contains 
dimeric P domains, which project out from the icosahedral shells and are responsible for the 
binding to the host cell receptors (Figure 2A,B). Intriguingly, the P domains (and in particular 
the receptor-binding P2 subdomains) have a much lower sequence identity than the overall 
genomes of GI and GII NoVs (approximately 25% (P2) compared to 50% overall [11*,13]). 
Moreover, the receptor binding sites are positioned at different locations at the P 
dimerization interface and have distinct structural characteristics [14*,8*,10] (Figure 2B-D). 
GI viruses bind HBGAs end-on and recognize mainly the terminal -Gal residue of blood 
group H-antigens (Figure 2C). Additional interactions are found to the Secretor fucose, which 
include hydrophobic interactions to a conserved tryptophan residue, kept in place by cation-
 stacking to a histidine. In A or B antigens, the -Gal binding site is instead occupied by the 
terminal -GalNAc or Gal residues characteristic for blood groups A and B, respectively, 
whereas the fucose residue is reoriented away from the conserved tryptophan into a 
secondary binding pocket (Figure 2C). In A antigens, the N-acetyl group of the terminal -
GalNAc residue mimics the interactions of the Secretor fucose (Figure 2C), whereas -Gal, 
characteristic of B antigens, lacks these additional interactions and binds poorly to GI NoVs, 
explaining why individuals with blood group B experience protection. GII NoVs mainly 
recognize -fucose, present either as Secretor or Lewis fucose in a large variety of HBGAs 
[20-25] (Figure 2D). It is therefore not surprising that GII NoVs exhibit a broad ABH blood 
group profile.  
Significantly less is known about RVs, both in terms of epidemiology and molecular 
mechanisms. RVs are double-stranded RNA viruses of the Reoviridae family, which form 
much larger viral particles than NoVs. VP8*, a subunit of the outer capsid protein VP4, is the 
functional equivalent of NoV’s P domain (Figure 2E,F). VP8* has a galectin fold, a fold known 
to recognize -Gal. However, in RVs the galactose binding site is blocked and a different site 
is involved in receptor recognition. For several decades, sialic acid has been known as the 
key cellular receptor of RVs, whereas the binding of HBGAs to certain RV strains was 
discovered only recently [26,27]. Nevertheless, the limited data that exist suggest that 
secretors are significantly more susceptible to RV infections than non-secretors [12], 
indicating that HBGAs may indeed be functional RV receptors. In 2012, a crystal structure of 
VP8* was reported in complex with a blood group A-trisaccharide [28*], occupying the same 
site that binds sialic acid in other RV strains. The major interactions were to the -GalNAc 
characteristic of blood group A and additional interactions to -Gal, whereas the Secretor-
fucose faced away from the HBGA binding site (Figure 2F). Nevertheless, glycan array data 
showed that this residue strongly enhances receptor binding [28*], which may be due to 
intramolecular conformational stabilization. Overall, binding specificity varies greatly 
between different RV strains, and even strains binding the same antigens exhibit 
considerable variation in molecular recognition [26,27,29]. Differences in the width of the 
receptor cleft may play a role in the different binding properties [10]. The structural 
adaptability of the VP8* binding site, including receptor-induced conformational changes, 
may furthermore lie at the heart of receptor-release prior to cell entry [22*] and of 
interspecies transmission [27,30]. 
Bacterial infections 
Many bacteria use lectins to attach to host cells (reviewed in this issue by Moonens & 
Remaut [31*]). One notable example is Helicobacter pylori, responsible for inducing stomach 
ulcers and gastric cancer. More than half of the world population is infected with this 
bacterium, which was declared a class I carcinogen by the WHO in 1994. The most virulent H. 
pylori strains mediate adhesion to the human host via the Blood group Antigen Binding 
Adhesin, BabA [32], which is present in large amounts in H. pylori membranes and facilitates 
the bacterial colonization of the stomach mucosa. Different H. pylori strains exhibit distinct 
blood group profiles [33]: in populations with high incidence of the blood group O 
phenotype, such as the natives of South America, specialist species predominate, while in 
Europe and the USA, which have a more diverse blood group pattern, generalist species of H. 
pylori are able to bind all three ABH blood group antigens. The different binding profiles are 
correlated with the presence of BabA variants with different specificities for ABH/Lewis 
glycans. Moonens et al. recently solved the crystal structures of several of these BabA 
variants in complexes with various HBGAs, revealing the molecular basis of this phenomenon 
[34**]. BabA’s interaction with host receptors is three-pronged (Figure 3A): (i) Its main 
anchor is the Secretor fucose, which is bound by a loop stabilized by a redox-sensitive 
disulfide bond called Cys-clasped Loop CL2, involving hydrogen bonds to several highly 
conserved amino acid residues. ii) The Asp-Ser-Ser triad of the Diversification Loop DL2 
specifically binds type 1 glycan receptors, ensuring tropism for the foveolar epithelium, 
which covers the inside of the stomach. iii) Blood group A/B-specific -GalNAc/Gal residues 
bind to a shallow pocket in the DL1 region. O-specific H. pylori strains exhibit a distinct 
sequence variation in this loop, where a proline in combination with a bulky residue (such as 
Asn, Asp, or Leu) sterically interferes with generalist binding. Additional phenotypes are the 
AB specialists, which bind more tightly to A/B-specific glycans due to additional interactions 
of the terminal -GalNAc/Gal residues with DL1, and the inverse specialists, which bind A/B- 
rather than O-specific glycans despite exhibiting the bulky Pro-Leu sequence, since a non-
functional DL2 loop allows for a slight rotation that prevents the steric clash (Figure 3A). 
Cholera is arguably the most well-known example of blood-group-dependent diseases. For 
50 years, individuals with blood group O have been known to experience more severe 
symptoms than those with other blood groups [35], although paradoxically they are less 
likely to be infected. The main culprit is the cholera toxin (CT), which after gaining entry to 
host cells, hijacks the host’s own endogenous pathways to trigger the opening of ion 
channels, inducing the massive secretory diarrhea typical of the disease. Secretors 
experience protection from cholera [36], which is in contrast to many other diseases. In the 
past few years, great strides were made in understanding the blood group association of 
cholera on a detailed molecular level. The primary receptor of the CT is the GM1 ganglioside, 
which binds to the toxin with nanomolar affinity [37]. That CT can also bind to HBGAs or 
analogs of these has been shown only recently [38,39]. Studies of chimera of the receptor-
binding subunits of CT and the homologous heat-labile toxin (LT) from enterotoxigenic 
Escherichia coli (ETEC) indicated that the toxins may harbor a second binding site [40,41], for 
HBGAs, that is spatially distinct from the GM1 binding site (Figure 3B). Subsequently, the 
crystal structure of LT was determined in complex with a blood-group-A-specific human milk 
oligosaccharide (HMO) resembling A-Lewisy, sparking a discussion as to why ETEC infections 
nevertheless do not show a strong blood group association [42*]. This is probably due to 
interference with LPS: in contrast to the CT, which is secreted as a soluble toxin, LT remains 
attached to outer membrane vesicles via LPS. Indications are that the binding sites for 
HBGAs and LPS overlap, interfering with LT binding to HBGAs [43], which would explain the 
lack of blood group association for ETEC infections. For cholera, conflicting data were 
published regarding the binding of two natural CT variants to HBGAs and HMO analogs 
[38,39,44]. The breakthrough came last year with the high-resolution structures of 
respective CT-complexes [45**] (Figure 3B) and supporting cell biological experiments [46], 
explaining all previous findings. Unexpectedly the blood group A determinant (and its HMO 
analog) bound in the opposite orientation compared to LT, showing that subtle amino acid 
differences in the secondary binding site can considerably modulate binding. Another 
unexpected result was the binding of H-determinants (Lewisy and its HMO-analog) in two 
alternative orientations. This rationalized the stronger binding of O-specific glycans 
compared to A- and B-determinants, where the A/B-specific -GalNAc/Gal residues can only 
be accommodated in one of the orientations. Again a fucose residue (generally the Lewis 
fucose) was shown to play the central role in binding, connecting two adjacent CT subunits. 
Even though binding affinities to HBGAs are only in the millimolar range and hence 
significantly weaker than to GM1 [37,45**], CT is capable of cooperatively binding these 
ligands with all five of its receptor-binding subunits, permitting high-avidity interaction with 
its target tissue. Stronger binding of the toxin to O-specific compared to A/B-specific glycans 
is consistent with the observed blood group profile of cholera. What remains to be further 
investigated is why secretors are protected.  
Other enteric pathogens known to bind HBGAs are Campylobacter jejuni [47] and Salmonella 
enterica serotype Typhimurium [48], although structural data regarding these interactions 
are not yet available. 
 
Infections of the airways 
While healthy airway mucus helps to expel microorganisms by coughing and sneezing, 
pathogenic mucus, as encountered in cystic fibrosis or chronic obstructive pneumonia, 
becomes a niche for chronic infection, leading to morbidity and mortality. The glycosylation 
of mucus changes during the course of pathologies, although it is not yet clear whether the 
changes are due to the disease itself, to associated inflammation or due to the presence of 
microbes [49-51]. Modifications in fucosylation, sulfatation and sialylation are generally 
observed in cystic fibrosis, but with different trends depending on N- or O-glycosylation. 
Opportunistic pathogens, often associated with hospital environments, include bacteria such 
as Pseudomonas aeruginosa and members of the Burkholderia complexes, and airborne 
fungi such as Aspergillus fumigatus. All of these pathogens bind to HBGAs, but so far only P. 
aeruginosa has been investigated for correlation between blood group and host 
susceptibility. 
P. aeruginosa infection is the leading cause of death of cystic fibrosis patients, and also 
affects immunocompromised patients. Conflicting data exist regarding its possible 
correlation with blood group phenotype. While the analysis of gene polymorphism in cystic 
fibrosis patients did not reveal any correlation between severity of P. aeruginosa infection 
and ABH, secretor or Lewis genotypes [52], other studies indicated a stronger susceptibility 
to P. aeruginosa sepsis in children with blood group B [53] and a correlation of external otitis 
with blood groups A or B [54]. P. aeruginosa interacts with host glycans mainly via two 
soluble lectins, the α-galactose specific LecA and the fucose-specific LecB, which have both 
been structurally characterized [55]. The LecA target is likely the αGal1-4Gal disaccharide 
present on globotriaosylceramide (Gb3) and blood group Pk and P1 antigens [56]. LecA 
binding to Gb3 triggers the uptake of the bacterium into airway cells in vitro [57]. LecB has a 
very strong affinity for fucose due to the rare chelation of two calcium ions, and its best-
known ligand is the Lewisa epitope. Two recent studies investigated the variations of LecB 
genes in more than 200 bacterial strains originating from natural or clinical environments 
[58,59**]. Sequence analysis revealed two main clusters that could be identified as PAO1-
like and PA14-like. The fucose binding site is conserved in all strains, with 13% variations of 
sequences between PAO1 and P14. Crystal structures and affinity analysis of two variants 
from PA14 [59**] and PA7 [58] strains confirmed that binding to fucose is conserved, 
indicating the importance of LecB for these bacteria. Furthermore, multivalent epitope 
presentation was shown to be critical. For example, the LecB variant from the pathogenic 
PA14 strain binds with very high affinity (Kd = 25 nM) to a biantennary N-glycan presenting 
two blood group H epitopes, corresponding to an affinity that is 10-fold higher than for 
isolated H-type 2 oligosaccharide (Kd = 200 nM) [59**]. 
The fucose-specific six-blade β-propeller fold represents another lectin family identified in 
lung pathogens, i.e. B. ambifaria (BambL) [60] and A. fumigatus (AFL or FleA) [61]. The 
biological role of these lectins is not yet entirely clear. For example, AFL was demonstrated 
to contribute to inflammation [61], but also stimulated macrophage killing, thus protecting 
the host [62*]. The 6-blade β-propeller fold is formed by a tandem repeat of one single chain 
in fungi or by trimerization of a much shorter chain in bacteria (Figure 4A,B). In AFL, the six 
binding sites exhibit minor differences in amino acid composition with variations in 
oligosaccharide preference as observed by soaking of crystals in a mixture of 
oligosaccharides [63*]. Nevertheless, both bacterial and fungal family members bind fucose 
in a unique conserved binding mode involving hydrogen bonds between an arginine and the 
O4 hydroxyl or ring oxygens, and between a Glu/Gln residue and the O3 and O4 hydroxyls as 
well as a CH-π interaction with a Tyr/Trp residue (Figure 4C-F). The general preference for 
blood group O (H-type 2) and Lewisy was rationalized through molecular modeling [64], 
showing that the binding pockets are well oriented for multivalent binding of terminal 
αFuc1-2Gal epitopes (Figure 4D). Apart for its preference for Lewisy, AFL binds to all 
fucosylated oligosaccharides, and therefore to all tissues expressing Lewis and ABH antigens. 
The αFuc1-3GlcNAc disaccharide present in Lewisx/y is also recognized, and analysis of the 
crystal complexes led to the surprising observation that the “closed” conformation, observed 
in solution, solid state and modeling [65], is forced into an “open” conformation when 
entering the binding sites (Figure 4E-F). A conserved aromatic residue appears to be 
responsible for guiding the fucose into the binding site by separating the fucose and 
galactose rings that are stacked together in solution [66**].  Opening of the canonical Lewisx 
conformation apparently involves the transient distortion of the central N-acetyl-
glucosamine ring, as shown by crystal structures of another family member, Ralstonia 
solanacearum lectin (RSL), in complexes with Lewisx and sialyl-Lewisx, combined with 
extensive molecular dynamics simulations [66**].  
 
Fighting back: glycans, glycocompounds and glycomimetics as anti-infectious 
agents 
Anti-infectious strategies can be based on competition with the attachment of pathogens to 
HBGAs on target tissues. Such protection is provided naturally by human milk, which 
contains a large variety of fucosylated and sialylated oligosaccharides (HMOs). These soluble 
oligosaccharides protect newborns from infections in a dual fashion, as anti-microbials and 
prebiotics [6*,67*]. Interesting examples, where structural information is available, are 
cholera [44,45**] and norovirus infections [68]. Building on the accumulated structural 
knowledge of lectin-oligosaccharide interactions, it has been possible to design 
glycomimetics with increased affinities for lectin receptors, achieving a stronger competition 
effect [69]. Classical strategies are centered on optimizing the binding energy between 
protein and carbohydrates, i.e. increasing the enthalpy of binding by maximizing the number 
of hydrogen bonds and/or hydrophobic contacts, and decreasing the entropy contribution 
by reducing the flexibility of the oligosaccharide. For example, the careful design of the 
aglycone (=non-sugar) part of a fucose derivative significantly increased the selectivity for its 
target B. cenocepacia BambL [70]. Similarly, a fucopyranoside glycomimetic inhibitor of A. 
fumigatus FleA was shown to inhibit binding and phagocytosis of conidia by macrophages 
[62*]. 
Another strategy is to design multivalent ligands that simultaneously bind to several binding 
sites of a multivalent receptor, resulting in a strong gain in avidity (=apparent multivalent 
affinity) [71*,72*]. A successful example is a divalent galactoside ligand of P. aeruginosa 
LecA, which was able to lower the cellular invasiveness of the bacteria by up to 90 % by 
chelating two neighboring receptor binding sites [73]. Other examples are the prevention of 
human immunodeficiency virus (HIV) transmission by glycodendrimers [74] and the design of 
multi-valent inhibitors against bacterial toxins [72*]. Based on high-throughput screening of 
compounds libraries, both in vitro and in silico, it is also possible to identify non-
carbohydrate glycomimetics able to compete in carbohydrate binding sites, as accomplished 
for noroviruses [75]. Yet another possibility is the design of HBGA-blocking antibodies as 
therapeutic agents ([76] and references therein). 
 
Conclusions and Perspective 
A large variety of human pathogens recognize blood group antigens. These include viruses, 
bacteria and fungi, which employ viral coat proteins, microbial adhesins, soluble lectins and 
toxins to invade and conquer their hosts [2]. In this review, we focus on human infections of 
the gastrointestinal tract and the airways. A common microbial strategy is to use HBGA 
binding for attachment and entry to the host cells. Secretors, who display these antigens on 
tissues exposed to the external environment and on their mucus, nurture symbionts [6*] but 
are also disproportionally affected by infectious diseases (however, as described below, 
hosts have their own measures to force selective pressures onto microbes, e.g. through 
blood group polymorphism, to prevent the eradication of entire populations [4,5*]). Another 
microbial strategy is to employ HBGA-binding toxins. Not discussed in this review is the 
molecular mechanism of parasitical malaria infection, where adhesins facilitate erythrocyte 
rosetting by binding primarily to blood group A antigens [77], explaining why individuals with 
blood group A are most severely affected by this disease. This has consequences on a 
population level, due to natural selection and evolution. The Ganges delta, for example, 
where both malaria and cholera are endemic, has a unique blood group profile, with the 
highest percentage of blood group B in the world. Blood group polymorphism is an 
important asset for surviving in this world [4]. Microbes respond by evolving many strains 
with different binding properties, but the hosts can fight back. Of particular importance is 
the continuously renewing mucus layer, which nurtures symbionts and helps expel 
pathogens [1,6*]. Another trick is human milk, which mimics HBGAs, serving as non-
degradable receptor decoy protecting human infants [67*]. The high fucose-content of 
human milk is likely of particular importance for the protective effect. Modified 
oligosaccharides, glycomimetics and dendrimers work in a similar way, with potential as 
medications and prophylactics [69,72*]. Enveloped viruses like influenza virus and HIV take 
their host’s membrane coats along on their journey to a new victim. This provides them with 
disguise, but can also elicit immune reactions against foreign blood groups. The molecular 
arms race is on, and we are now beginning to understand its molecular underpinnings, 
providing us with new tools to fight disease. 
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Figure Legends 
 
Figure 1: Biosynthetic pathways of type 1 and type 2 human histo-blood group antigens 
(HBGAs). Carbohydrate symbols are shown in the standard schematic representation 
introduced by the Consortium for Functional Glycomics. H-type 1 (3-linkage) and H-type 2 
(4) precursors are fucosylated by -1,2-fucosyltransferase (FUT2) or -1,3/4-
fucosyltransferase (FUT3/4), adding the Secretor fucose and Lewis fucose, respectively. 
Blood group H determinants (characteristic of blood group O) can subsequently be modified 
by the action of A or B glycosyltransferases, which add an -GalNAc or -Gal residue to -
Gal, to give rise to blood group A or B antigens, respectively. Non-secretors lack the FUT2 
gene and can therefore only synthesize the smallest Lewis antigens, Lewisa and Lewisx.  
 
Figure 2: HBGA recognition by noro- and rotaviruses. (A) Structure of NoV capsid (PDB 1IHM 
[19*]). (B) Structure of individual protruding P domains (dimers). Gray  P domain of GI NoV 
in complexes with H-pentasaccharide (green sticks; PDB 2ZL6 [14*]) and A-trisaccharide 
(cyan sticks; PDB 2ZL7 [14*]). Green/slate  GII P domain bound to A-trisaccharide (yellow 
sticks; PDB 3SLD [22*]). (C) Top view of the GI and GII P domain complexes shown in (B) and 
close-up view of GI NoV interaction with H-type 1 pentasaccharide (green sticks, with fucose 
in magenta) and the corresponding A-trisaccharide (cyan sticks, including fucose). Important 
amino acid and carbohydrate residues are labeled, H-type 1 residues in italics. H-bonds are 
indicated by red dashed lines, and the hydrophobic interaction to Trp with yellow filled 
circles. Note that the acetamido group of GalNAc characteristic of A antigens partially mimics 
the interactions of the H-type 1 fucose. (D) Top view of the GII P domain complex shown in 
(B), and details of GII NoV interaction with A-trisaccharide (yellow sticks, fucose in magenta). 
The virus is anchored to the fucose residue, while the GalNAc residue provides only limited 
contacts. (E) RV capsid structure (PDB 4V7Q [78*]) with protruding VP4 spikes (teal). (F) Top 
domains of VP4, with A-trisaccharide (yellow sticks, with fucose in magenta) bound to the 
VP8* domain. The close-up view shows details of VP8* A-trisaccharide interaction (PDB 
4DRV [28]). Carbohydrate residues are labeled, the fucose is highlighted in magenta and H-
bonds are indicated with red dashes. Main interactions are to the GalNAc residue 
characteristic of A antigens. 
  
Figure 3: HBGA-interactions of selected bacterial pathogens of the gastrointestinal tract. (A) 
Molecular basis of H. pylori adaptation to human HBGA polymorphism. The H. pylori adhesin 
BabA binds to HBGAs with three loops (DL1, CL2, DL2), displaying significant variation 
between different strains. For example, ABO generalists can accommodate the Gal (green 
sticks) or GalNAc residues (not shown) characteristic of B or A antigens, respectively, 
whereas bulky residues in DL1 prevent HBGA binding due to steric interference, leading to 
O-specialists (close-up view). This panel is reproduced with permission from [31*]. (B) 
Molecular basis of cholera blood group dependence. The culprit is the cholera toxin (CT; 
cartoon representation), which binds to HBGAs (box) and GM1 (green sticks; PDB 3CHB [79]). 
Several CT structures are superimposed. The CT A subunit is colored purple (PDB 1LTS [80]), 
the CT B pentamer blue, gray and magenta (PDB 3CHB [78]). A close-up view shows the 
detailed interactions of CT with the H-tetrasaccharide (white sticks; PDB 5ELB [45**]) and 
the A-pentasaccharide (colored sticks; PDB 3ELD [45**]). The color code is the same as for 
the standard schematic representations shown below. Note that H-tetra can bind in two 
orientations, whereas the A-pentasaccharide (BGA or HMO) binds in a single orientation (Se 
Fuc, Secretor fucose; Le Fuc, Lewis fucose).  
 
Figure 4: HBGA-pathogen interactions of selected airway infections. (A,B) Overall 
representations of the 6-bladed -propeller folds of BambL in complex with the H-type 2 
determinant (A, PDB 3ZZV [60]) and AFL (FleA) with a blood group A determinant (B, PDB 
4AH4 [63]). Coloring is by protein chain or blade, respectively. (C) Close-up view of the 
fucose binding site 3 in AFL. (D-F) Surface representations of the binding of H-type 2 (D; PDB 
3ZZV [60]) and Lewisx (E, PDB 3ZW1 [60]) determinants in the intramolecular binding site of 
BamBL, and Lewisy (F, PDB 4D4U [63]) in binding site 3 of AFL.   
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(cyan sticks; PDB 2ZL7 [14*]). Green/slate  GII P domain bound to A-trisaccharide (yellow 
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the interactions of the H-type 1 fucose. (D) Top view of the GII P domain complex shown in 
(B), and details of GII NoV interaction with A-trisaccharide (yellow sticks, fucose in magenta). 
The virus is anchored to the fucose residue, while the GalNAc residue provides only limited 
contacts. (E) RV capsid structure (PDB 4V7Q [78*]) with protruding VP4 spikes (teal). (F) Top 
domains of VP4, with A-trisaccharide (yellow sticks, with fucose in magenta) bound to the 
VP8* domain. The close-up view shows details of VP8* A-trisaccharide interaction (PDB 
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bonds are indicated with red dashes. Main interactions are to the GalNAc residue 
characteristic of A antigens. 
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determinant (A, PDB 3ZZV [60]) and AFL (FleA) with a blood group A determinant (B, PDB 
4AH4 [63]). Coloring is by protein chain or blade, respectively. (C) Close-up view of the 
fucose binding site 3 in AFL. (D-F) Surface representations of the binding of H-type 2 (D; PDB 
3ZZV [60]) and Lewisx (E, PDB 3ZW1 [60]) determinants in the intramolecular binding site of 
BamBL, and Lewisy (F, PDB 4D4U [63]) in binding site 3 of AFL.  
 
